PHARMA MAR, S.A. «12345...» Page 2 out of 24 19/12/2024 08:55 PHARMA MAR, S.A. On business and financial situation The Company completes recruitment for phase III LAGOON study with Zepzelca® (lurbinectedin) for the treatment of Small Cell Lung Cancer. Register number: 31838 18/12/2024 17:48 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company informs that it will carry out a program to buy-back treasury shares Register number: 31830 18/12/2024 17:41 PHARMA MAR, S.A. On corporate governance The Company reports on the approval of the Regulations of the Audit Committee and of the Appointments and Compensation and Sustainability Committee, as well as the amendment of the Board of Directors Regulations. Register number: 31829 03/12/2024 09:36 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in China. Register number: 31595 27/11/2024 08:26 PHARMA MAR, S.A. Total number of voting rights and capital Total number of voting rights and capital after capital reduction by means of the redemption of treasury shares. Register number: 31509 21/11/2024 17:39 PHARMA MAR, S.A. Other relevant information Registration within the Madrid Mercantile Registry of the resolution to reduce capital by means of the redemption of own shares. Register number: 31471 20/11/2024 12:22 PHARMA MAR, S.A. On business and financial situation The Company informs that the General Court of the European Union has declared that there is no longer any need to adjudicate and ordered the European Commission to pay Pharma Mar's costs. Register number: 31445 05/11/2024 08:27 PHARMA MAR, S.A. On business and financial situation The Company announces a US$10 million milestone payment from Janssen Products LP. Register number: 31202 29/10/2024 17:43 PHARMA MAR, S.A. On financial instruments Implementation of the reduction of share capital by means of the redemption of own shares approved by the General Shareholders’ Meeting of 29 May 2024 under item number four of the agenda. Register number: 31075 29/10/2024 17:38 PHARMA MAR, S.A. On business and financial situation The Company files third quarter 2024 financial information. Register number: 31072 Page 2 out of 24 «12345...»
